Sangamo BioSciences Inc. (NASDAQ:SGMO)’s share price was up 4.3% on Wednesday . The stock traded as high as $6.89 and last traded at $6.85, with a volume of 581,607 shares trading hands. The stock had previously closed at $6.57.

Several equities analysts recently weighed in on SGMO shares. Jefferies Group reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Sangamo BioSciences in a research note on Thursday, June 9th. Zacks Investment Research downgraded Sangamo BioSciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 5th. Wells Fargo & Co. started coverage on Sangamo BioSciences in a research note on Tuesday, May 3rd. They issued a “buy” rating for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Sangamo BioSciences in a research note on Friday, May 6th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Sangamo BioSciences has an average rating of “Buy” and a consensus target price of $16.75.

The company’s market cap is $482.17 million. The company’s 50 day moving average price is $5.90 and its 200 day moving average price is $6.08.

Sangamo BioSciences (NASDAQ:SGMO) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.14. The business had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.38 million. The company’s revenue was down 56.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.17) earnings per share. On average, equities analysts forecast that Sangamo BioSciences Inc. will post ($0.98) earnings per share for the current year.

A hedge fund recently raised its stake in Sangamo BioSciences stock. Royce & Associates LLC increased its stake in shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) by 47.1% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 312,100 shares of the biopharmaceutical company’s stock after buying an additional 100,000 shares during the period. Royce & Associates LLC owned approximately 0.45% of Sangamo BioSciences worth $2,849,000 at the end of the most recent reporting period.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.